NeuroSense Therapeutics announced that findings from its Phase 2b PARADIGM study on the ALS drug PrimeC will be presented at the 2026 NEALS Consortium meeting. These clinical and biomarker results support the design of the upcoming Phase 3 PARAGON trial, aiming for a more efficient development process. PrimeC targets multiple pathways involved in ALS progression and has shown slower functional decline in patients compared to placebo. The company has FDA clearance to start the Phase 3 trial, primarily in the U.S., marking a significant step toward potential ALS treatment.
NeuroSense's ALS drug PrimeC clinical progress is the story, here is Pluang's health sector snapshot as of Oct 29, 2026 22:21 WIB: Out of 150 priced health-sector US stocks, 116 rose and 34 fell today. Notable movers include Inovio Pharmaceuticals Inc (INO) at USD 0.81 with a 1-day change of -12.75% and a typical hold time of 43 days, Citius Pharmaceuticals Inc (CTXR) at USD 0.60 up 10.64% with a typical hold time of 18 days, and Eli Lilly And Co (LLY) at USD 1,373.56 up 6.58% with a typical hold time of 94 days and 71% buy activity on Pluang orders.
The inaugural SportsTech Breakthrough Awards recognized leading companies and technologies advancing sports technology globally. Winners span categories like athlete performance, wearables, AI analytics, fan engagement, and smart stadium solutions, h...
The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...
AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
